November 16, 2020
Elite Diagnostics Limited (ELITE), for the three months ended September 30, 2020 reported that revenue decreased by 7% to total $109.72 million compared to $118 million for the same period in 2019. The company highlighted, “the company’s 1st quarter revenue was affected by Covid-19 with reduction of operating hours and reduced procedures. Currently the company’s operational hours are back to normal. An unusually lengthy breakdown of the CT also impacted our revenues during the 1st quarter. Along with our regular Preventative Maintenance of the machines, the company has invested in equipment and parts to reduce some of the downtime of the machine breakdowns.”
ELITE added, “the St Ann location revenue is increasing month over month since all modalities became operational in the 1st quarter 2020. The company is cautiously optimistic as the effects of Covid19 more negatively impacts the rural areas of the country.”
Cost of sales for the period showed an increase of 6%, moving from $39.83 million to $42.34 million. As such, gross profit amounted to $67.37 million, a decrease of 14% when compared to $78.17 million recorded last year.
Administrative expenses saw a jump of 14%, to total $45.56 million (2019: $40.13 million) while other income amounted to $20,000 (2019: $576). In addition, Depreciation and Amortization amounted to $25.12 million relative to $17.43 million a year ago.
As such, loss from operations totalled $3.28 million, versus a profit of $20.62 million booked in 2019. Loss on Foreign exchange for the period totalled $2.09 million, relative to a gain of $1.03 million recorded same time in 2019. Additionally, the company’s finance cost ended at $4.97 million (2019: $4.95 million).
Loss before tax totalled $10.34 million compared to a profit of $16.69 million recorded last year. No taxes were booked for the period.
Therefore, net loss for the period totalled $10.24 million, versus a profit of $16.69 million the prior financial year.
Loss per share (LPS) for the period totalled $0.029 (2019: EPS $0.047). The twelve-month trailing LPS is $0.052. The number of shares used in our calculations amounted to 353,400,000 units. The stock last traded on November 16, 2020 at $3.11.
The company noted, “The company continues to see steady demand for imaging services at all locations. The negative effects of Covid-19 and equipment downtime remains a challenge, however the company is hopeful to see enhanced performance due to growth of the St Ann location and longer operating hours.”
Balance Sheet at a glance:
As at September 30, 2020, total assets amounted to $678.72 million, down $1.82 million from the balance of $680.54 million for last year. This marginal decrease in total assets was mainly as a result of a decrease in ‘Cash and cash equivalents’ from $75.04 million to $38.71 million.
Shareholders’ Equity of $449.42 million was reported (2019: $467.90 million) which resulted in a book value per share of $1.27 (2019: $1.32).
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.